Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2014

View Archived Issues

Sanofi reports progress across key programs in fourth quarter 2013

Revive Therapeutics reports interim data from phase IIa study of REV-001

Canadian researchers patent new immunoglobulin constructs

New vaccine company Abivax created

Pierre Fabre obtains worldwide rights to immune checkpoint modulator from Aurigene

Development of a dual serotonin receptor antagonist for the treatment of patients with dementia

FDA grants full approval to Synribo for injection

X-Chem licenses epigenetic program to Bayer Pharma

Aerpio Therapeutics begins phase II study of AKB-9778 in diabetic macular edema

Merck & Co. presents new ROMK blockers

Sphaera Pharma designs new signal transduction inhibitors for cancer

Bristol-Myers Squibb prepares novel P2Y1 receptor antagonists for thrombosis

Agenus aims to develop cancer immunotherapy program with acquisition of 4-Antibody

Bionomics prepares new nicotinic acetylcholine receptor modulators

Scientists at Bristol-Myers Squibb patent new AAK1 inhibitors for pain and other disorders

Preliminary phase II results presented for pazopanib/paclitaxel combination in urothelial carcinoma

Decreased GATA1 mRNA expression associated with poor clinical prognosis in ccRCC

Lilly describes nonsteroidal glucocorticoid antagonist that minimizes treatment-related weight gain

Otsuka Pharmaceutical recaps highlights of third quarter of fiscal 2013

Isis Pharmaceuticals provides update on trials of ISIS-SMNRx in spinal muscular atrophy

Ampio reports preliminary findings from biochemical analysis from SPRING study

Alexion, Prothelia and University of Nevada enter agreements for laminin-111

SwissMedic approves Actelion's Opsumit for pulmonary arterial hypertension

AVEO and Astellas to end worldwide tivozanib collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...